Literature DB >> 19424760

Targeting gelatinases with a near-infrared fluorescent cyclic His-Try-Gly-Phe peptide.

Wei Wang1, Ruping Shao, Qingping Wu, Shi Ke, John McMurray, Frederick F Lang, Chusilp Charnsangavej, Juri G Gelovani, Chun Li.   

Abstract

PURPOSE: The purpose of the study is to synthesize and characterize near-infrared (NIR) fluorescence imaging probes targeted to gelatinases. PROCEDURES: A phage display-selected cyclic peptide containing the His-Try-Gly-Phe (HWGF) motif was used as the lead compound. Structure-activity relationship analysis was used to identify stable and potent gelatinase inhibitors suitable for NIR imaging applications.
RESULTS: Replacing the S-S bond in cyclic peptide c(CTTHWGFTLC)NH(2) (C1) with an amide bond between the epsilon-amino group of Lys and the side chain of Asp resulted in a significant increase in stability and a fourfold increase in gelatinase inhibition of the resulting peptide, c(KAHWGFTLD)NH(2) (C6). Conjugation of Cy5.5 to C6 led to Cy5.5-C6, which was selectively taken up by MMP-2 expressing human glioma U87 cells. In vivo, selective accumulation of Cy5.5-C6, but not Cy5.5-C1 or a Cy5.5-scrambled peptide conjugate, was visualized in intratibial prostate PC-3 tumors 48 h after their intravenous injection. Moreover, Cy5.5-C6 was readily visualized in orthotopically inoculated U87 brain tumors.
CONCLUSIONS: Cy5.5-C6 may be a useful agent for molecular imaging of gelatinases. The approach of producing stable cyclic peptides through side chain amide linkage should be applicable to other peptide-based imaging agents.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19424760      PMCID: PMC3435882          DOI: 10.1007/s11307-009-0219-y

Source DB:  PubMed          Journal:  Mol Imaging Biol        ISSN: 1536-1632            Impact factor:   3.488


  30 in total

1.  MMP-2 colocalizes with caveolae on the surface of endothelial cells.

Authors:  A Puyraimond; R Fridman; M Lemesle; B Arbeille; S Menashi
Journal:  Exp Cell Res       Date:  2001-01-01       Impact factor: 3.905

2.  Cyanine dye labeled vasoactive intestinal peptide and somatostatin analog for optical detection of gastroenteropancreatic tumors.

Authors:  A Becker; C Hessenius; S Bhargava; C Grötzinger; K Licha; J Schneider-Mergener; B Wiedenmann; W Semmler
Journal:  Ann N Y Acad Sci       Date:  2000       Impact factor: 5.691

3.  In vivo localization of gelatinases (MMP-2 and -9) by in situ zymography with a selective gelatinase inhibitor.

Authors:  E Pirilä; P Maisi; T Salo; E Koivunen; T Sorsa
Journal:  Biochem Biophys Res Commun       Date:  2001-09-28       Impact factor: 3.575

4.  In vivo molecular target assessment of matrix metalloproteinase inhibition.

Authors:  C Bremer; C H Tung; R Weissleder
Journal:  Nat Med       Date:  2001-06       Impact factor: 53.440

Review 5.  Fluorescence imaging with near-infrared light: new technological advances that enable in vivo molecular imaging.

Authors:  Vasilis Ntziachristos; Christoph Bremer; Ralph Weissleder
Journal:  Eur Radiol       Date:  2002-07-19       Impact factor: 5.315

6.  Membrane type 1-matrix metalloproteinase (MT1-MMP) and MMP-2 immunolocalization in human prostate: change in cellular localization associated with high-grade prostatic intraepithelial neoplasia.

Authors:  J Upadhyay; B Shekarriz; J A Nemeth; Z Dong; G D Cummings; R Fridman; W Sakr; D J Grignon; M L Cher
Journal:  Clin Cancer Res       Date:  1999-12       Impact factor: 12.531

7.  Valine-based biphenylsulphonamide matrix metalloproteinase inhibitors as tumor imaging agents.

Authors:  Ruth Oltenfreiter; Ludovicus Staelens; Veerle Kersemans; Bart Cornelissen; Francis Frankenne; Jean-Michel Foidart; Christophe Van de Wiele; Guido Slegers
Journal:  Appl Radiat Isot       Date:  2006-03-20       Impact factor: 1.513

Review 8.  Development of matrix metalloproteinase inhibitors in cancer therapy.

Authors:  M Hidalgo; S G Eckhardt
Journal:  J Natl Cancer Inst       Date:  2001-02-07       Impact factor: 13.506

9.  Optical imaging of matrix metalloproteinase-2 activity in tumors: feasibility study in a mouse model.

Authors:  C Bremer; S Bredow; U Mahmood; R Weissleder; C H Tung
Journal:  Radiology       Date:  2001-11       Impact factor: 11.105

10.  In vivo near-infrared fluorescence imaging of osteoblastic activity.

Authors:  A Zaheer; R E Lenkinski; A Mahmood; A G Jones; L C Cantley; J V Frangioni
Journal:  Nat Biotechnol       Date:  2001-12       Impact factor: 54.908

View more
  11 in total

Review 1.  Peptides and peptide hormones for molecular imaging and disease diagnosis.

Authors:  Seulki Lee; Jin Xie; Xiaoyuan Chen
Journal:  Chem Rev       Date:  2010-05-12       Impact factor: 60.622

2.  Characterization of chemical, radiochemical and optical properties of a dual-labeled MMP-9 targeting peptide.

Authors:  Ali Azhdarinia; Nathaniel Wilganowski; Holly Robinson; Pradip Ghosh; Sunkuk Kwon; Zawaunyka W Lazard; Alan R Davis; Elizabeth Olmsted-Davis; Eva M Sevick-Muraca
Journal:  Bioorg Med Chem       Date:  2011-05-06       Impact factor: 3.641

Review 3.  Imaging Inflammation - From Whole Body Imaging to Cellular Resolution.

Authors:  Tuula Peñate Medina; Jan Philip Kolb; Gereon Hüttmann; Robert Huber; Oula Peñate Medina; Linh Ha; Patricia Ulloa; Naomi Larsen; Arianna Ferrari; Magdalena Rafecas; Mark Ellrichmann; Mariya S Pravdivtseva; Mariia Anikeeva; Jana Humbert; Marcus Both; Jennifer E Hundt; Jan-Bernd Hövener
Journal:  Front Immunol       Date:  2021-06-24       Impact factor: 7.561

4.  Multiple target-specific molecular imaging agents detect liver cancer in a preclinical model.

Authors:  S Ke; F Zhang; W Wang; X Qiu; J Lin; A G Cameron; C Zou; X Gao; C Zou; V F Zhu; M Li
Journal:  Curr Mol Med       Date:  2012-09       Impact factor: 2.222

5.  Targeting bladder tumor cells in voided urine of Chinese patients with FITC-CSNRDARRC peptide ligand.

Authors:  Xing-You Jia; Qi Yu; Zhe-Hui Zhang; Xiao-Feng Yang
Journal:  Onco Targets Ther       Date:  2012-05-07       Impact factor: 4.147

6.  Systemic delivery of protein nanocages bearing CTT peptides for enhanced imaging of MMP-2 expression in metastatic tumor models.

Authors:  Takahito Kawano; Masaharu Murata; Jing Shu Piao; Sayoko Narahara; Nobuhito Hamano; Jeong-Hun Kang; Makoto Hashizume
Journal:  Int J Mol Sci       Date:  2014-12-24       Impact factor: 5.923

7.  MMPs and angiogenesis affect the metastatic potential of a human vulvar leiomyosarcoma cell line.

Authors:  Carlotta Alias; Laura Rocchi; Domenico Ribatti; Stefano Caraffi; Alessandra D'Angelo; Roberto Perris; Domenica Mangieri
Journal:  J Cell Mol Med       Date:  2015-05-22       Impact factor: 5.310

Review 8.  A Comprehensive Review of Non-Covalent Radiofluorination Approaches Using Aluminum [18F]fluoride: Will [18F]AlF Replace 68Ga for Metal Chelate Labeling?

Authors:  Cyril Fersing; Ahlem Bouhlel; Christophe Cantelli; Philippe Garrigue; Vincent Lisowski; Benjamin Guillet
Journal:  Molecules       Date:  2019-08-07       Impact factor: 4.411

9.  Development of a Novel PET Tracer [18F]AlF-NOTA-C6 Targeting MMP2 for Tumor Imaging.

Authors:  Qinghua Liu; Donghui Pan; Chao Cheng; Dazhi Zhang; Anyu Zhang; Lizhen Wang; Hongdie Jiang; Tao Wang; Hongrui Liu; Yuping Xu; Runlin Yang; Fei Chen; Min Yang; Changjing Zuo
Journal:  PLoS One       Date:  2015-11-05       Impact factor: 3.240

10.  Multi-modality imaging to determine the cellular heterogeneity of nasopharyngeal carcinoma components.

Authors:  Weidong Zhang; Yanling Zhang; Shi Ke; Mingjian Lu; Guang Yang; Tao Zhang; Jianjun Han; Zhenyin Liu; Wei Wang; Henry Ran; Chaoxia Zou; Shaofan Hu; Guangtao Lei; Chuanxing Li; Fujun Zhang
Journal:  Oncotarget       Date:  2014-04-30
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.